Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD0865 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| AZD0865 | DRUG | - |
Inclusion Criteria: * Identification of their main symptom as heartburn defined as a burning feeling behind the breastbone. * Have at least a 6-month history of heartburn and at least 4 days of episodes of heartburn with at least overall moderate intensity during the last 7 days prior to visit 1. *...
AZD0865 is an investigational small molecule being developed for gastroesophageal reflux disease (GERD), specifically for GERD with erosive esophagitis and GERD without erosive esophagitis. It is a gastrointestinal therapeutic currently in Phase 2 clinical development.
AZD0865 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The drug is in Phase 2 clinical development for the treatment of GERD with and without erosive esophagitis.
AZD0865 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. Two Phase 2 trials have been completed for the drug.
AZD0865 has been studied in two completed Phase 2 clinical trials: NCT00206245, a dose-finding study in patients with GERD and erosive esophagitis, and NCT00206284, a dose-finding study in patients with GERD without erosive esophagitis. Both trials enrolled 1400 participants.
No, AZD0865 is not the same as esomeprazole. In clinical trials, AZD0865 was studied in comparison with esomeprazole, which is an approved proton pump inhibitor used as an active control. AZD0865 is a separate investigational compound being developed by AstraZeneca.